Learn More
Medchemexpress LLC RP-1664 | 2980682-00-4 | 98.77% | 514.55 | 5 MG

Supplier: Medchemexpress LLC HY1727375MG
RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. It demonstrates selectivity over related kinases like AURKA/B and PLK1. This compound disrupts centriole biogenesis in cancer cells, leading to an accumulation of PLK4 and p21 protein. RP-1664 shows increased sensitivity in TRIM37-high-expressing cells or tumors and exhibits anti-tumor activity in breast cancer and neuroblastoma research.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.